Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...

Serious infections significantly increase the mortality risk among adults with chronic liver disease, including those without cirrhosis.

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

Current guidelines for patients with cirrhosis and upper-GI bleeding recommend 5 to 7 days of antibiotic prophylaxis to ...

One of the challenges with liver disease is that it can be a silent threat. In its early stages, it may cause only vague ...

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...